223.50
+6.50
+(3.00%)
At close: January 17 at 5:02:47 PM GMT+1
Breakdown
TTM
9/30/2024
9/30/2023
9/30/2022
9/30/2021
Total Revenue
624,796.62
624,796.62
446,871.57
166,860.94
128,627.45
Cost of Revenue
433,932.00
433,932.00
315,048.90
118,355.48
98,362.17
Gross Profit
190,864.62
190,864.62
131,822.67
48,505.46
30,265.28
Operating Expense
81,914.66
81,914.66
62,468.86
36,242.24
18,914.16
Operating Income
108,949.96
108,949.96
69,353.81
12,263.21
11,351.12
Net Non Operating Interest Income Expense
-3,810.31
-3,810.31
-1,259.36
-1,362.52
-778.31
Pretax Income
104,726.11
104,726.11
65,674.90
12,288.92
10,221.41
Tax Provision
20,089.89
20,089.89
13,222.71
1,987.72
1,837.60
Net Income Common Stockholders
84,636.22
84,636.22
52,452.19
10,301.21
8,383.81
Diluted NI Available to Com Stockholders
84,636.22
84,636.22
52,452.19
10,301.21
8,383.81
Basic EPS
9.92
--
6.15
1.21
0.98
Diluted EPS
9.92
--
6.15
1.21
0.98
Basic Average Shares
8,529.13
--
8,529.13
8,529.13
8,529.13
Diluted Average Shares
8,529.13
--
8,529.13
8,529.13
8,529.13
Total Operating Income as Reported
107,817.97
107,817.97
67,862.32
17,617.90
11,187.18
Total Expenses
515,846.66
515,846.66
377,517.76
154,597.73
117,276.33
Net Income from Continuing & Discontinued Operation
84,636.22
84,636.22
52,452.19
10,301.21
8,383.81
Normalized Income
84,636.22
84,636.22
52,452.19
4,679.67
8,263.87
Interest Income
541.29
541.29
1,149.79
150.10
123.12
Interest Expense
4,351.60
4,351.60
2,409.15
1,456.21
483.93
Net Interest Income
-3,810.31
-3,810.31
-1,259.36
-1,362.52
-778.31
EBIT
109,077.71
109,077.71
68,084.05
13,745.13
10,705.34
EBITDA
125,434.11
125,434.11
82,862.12
25,784.60
18,680.18
Reconciled Cost of Revenue
433,932.00
433,932.00
315,048.90
118,355.48
98,362.17
Reconciled Depreciation
16,356.40
16,356.40
14,778.07
12,039.47
7,974.84
Net Income from Continuing Operation Net Minority Interest
84,636.22
84,636.22
52,452.19
10,301.21
8,383.81
Total Unusual Items Excluding Goodwill
-60.16
--
-2,527.58
6,706.27
146.23
Total Unusual Items
-60.16
--
-2,527.58
6,706.27
146.23
Normalized EBITDA
125,434.11
125,434.11
82,862.12
19,078.33
18,533.95
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
--
1,084.73
26.29
9/30/2021 - 8/9/2011
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
MCAP.ST MedCap AB (publ)
411.00
-29.98%
SMSMED.CO Scandinavian Medical Solutions A/S
5.58
+0.36%
OSSD.ST OssDsign AB (publ)
10.40
-1.70%
IOB.DU Ion Beam Applications SA
12.98
-2.41%
NEOLA.ST Neola Medical AB (publ)
2.5400
-0.78%
2SE.F Sequana Medical NV
2.5400
-1.17%
CYBQF CYBERDYNE Inc.
1.0350
0.00%
8C4.F CYBERDYNE Inc.
1.0440
-0.19%
2SE.SG Sequana Medical NV
2.5400
-2.68%
ABT.VI Abbott Laboratories
110.40
+0.84%